Tuesday, April 9th 2019
|15:00||Opening Welcome Desk|
in the presence of grand-children and great-grandchildren of Jules Bordet, discoverer of Bordetella pertussis.
Welcome address by Prof. Oberdan Leo, Vice-Rector of the Université Libre de Bruxelles. The work of Jules Bordet, as it is remembered 100 years after the Nobel Prize.
Mrs. Nathalie Devroey, Great-granddaughter of Jules Bordet. A portrait of Jules Bordet as a person.
|16:30||James D. Cherry – University of California, USA|
The 112-years odyssey of pertussis and pertussis vaccines – mistakes made and implications for the future.
|17:00||Special opening session|
on Adenylate Cyclase Toxin in honour of Erik Hewlett
|17:00||Damron F. Heat – West Virginia University, USA|
For the love of ACT
|17:20||Hewlett Erik – University of Virginia, USA|
The saga of Bordetella adenylate cyclase toxin: how did we get here and where are we going?
|17:50||Ladant Daniel – Institut Pasteur, France|
The adenylate cyclase toxin form Bordetella pertussis: a jack of many trades.
|18:10||Sebo Peter – Institute of Microbiology, Czech Academy of Sciences, Czech Republic|
The why and what for of Bordetella pertussis adenylate cyclase toxin.
Welcome reception at the Museum of Medicine
Wednesday, April 10th 2019
|08:00||Opening Welcome Desk|
|9:00||Session 1: Clinical and epidemiological aspects of pertussis|
Chair: K. Edwards & J. Cherry
|9:00||Klein Nicola – Kaiser Permanente Vaccine Study Center, USA|
Evolving pertussis epidemiology: impact of a mature acellular pertussis vaccine program.
|9:30||Read Robert – University of Southampton, UK|
A human controlled infection model of Bordetella pertussis colonisation.
|10:00||Campbell Helen – Public Health England, UK|
An update on the maternal pertussis immunization programme in England.
|10:20||Marshall Helen – The University of Adelaide, Australia|
Severe hospitalized pertussis and effectiveness of maternal vaccination against severe pertussis in infants aged <6 months
|11:00||Edmunds Matt – Public Health England, UK|
Evaluation of symptomatic and asymptomatic transmission of Bordetella pertussis during an outbreak in a secondary boarding school, England, 2018.
|11:20||Raeven Rene – intravacc, The Netherlands|
Immunoproteomic profiling of Bordetella pertussis infection-induced responses reveals distinct antibody responses between human individuals with different pertussis immunization background.
|11:40||Fry Norman – Public Health England, UK|
External quality assessment for the detection of Bordetella pertussis by PCR in Europe.
|12:00||Walking Lunch & poster viewing|
|14:00||Session 2: Bordetella biology and pathogenesis|
Chair: R. Fernandez & M.E. Rodriguez
|14:00||Merkel Tod – Food and Drug Administration, USA|
Pertussis pathogenesis and transmission: insights from the baboon model.
|14:30||Jacob-Dubuisson Françoise – Center for Infection and Immunity of Lille, France|
Copper homeostasis in Bordetella pertussis in relation with pathogenesis.
|15:00||Naninck Thibaut – CEA, France|
In vivo imaging of B. pertussis colonization and interactions with the host by probe-based confocal laser endomicroscopy in the baboon respiratory tract.
|15:20||Ernst Katharina – Ulm University Medical Center, Germany|
Intoxication of mammalian cells with pertussis toxin is impaired by pharmacological cyclophilin inhibitors.
|16:00||Scanlon Karen – University of Maryland, USA|
Developmentally regulated angiotensin system potentiates severe manifestations of disease in an infant mouse model of pertussis.
|16:20||Ifill Gyles – The University of British Columbie, Canada|
Altered RNA turnover in Bordetella pertussis provides insight into regulatory RNAs implicated in pathogenesis.
|16:40||MacArthur Iain – University of Bath|
Mutations in Bordetella pertussis acr cause sensitivity to hydrophobic molecules and fatty acids.
|17:00||Chen Qing – Food and Drug Administration, USA|
Both RisA and RisR response regulators are required for the activation of Bvg-repressed vrgs in Bordetella pertussis.
|17:20||Poster viewing & fresh drinks|
Thursday, April 11th 2019
|9:00||Session 3: Immunity and Vaccination|
Chair: N. Carbonetti & F. Mascart
|9:00||Mills Kingston – Trinity College Dublin, Ireland|
Mechanism of sustained natural and vaccine-induced protective immunity against nasal colonization with Bordetella pertussis.
|9:30||Cartelle Gestal Monica – University of Georgia, USA|
Immunomodulation suppresses innate and adaptive immunity to Bordetella infection.
|09:50||Kroes Michel – RIVM, The Netherlands|
Activation of human NK cells by Bordetella pertussis requires inflammasome activation in macrophages.
|10:10||Mionnet Cyrille – Ciml Immunology, France|
Pertussis toxin is critical to generate tissue resident memory T cell populations in the lung of Bordetella pertussis infected mice.
|11:00||Hozbor Daniela – Universida Nacional de La Plata, Argentina|
Outer membrane vesicles as vaccine candidates against infections caused by different species of Bordetella genus.
|11:30||Da Silva Antunes Ricardo – La Jolla Institute for Immunology, USA|
Differences in T cell responses to Bordetella pertussis in adults as a function of whole cell versus acellular childhood vaccination.
|11:50||Kapil Parul – FDA, USA|
Polarization of acellular pertussis vaccine-primed immune responses to the Th17 response.
|12:10||Ardanuy Jeremy – University of Maryland, USA|
Type I and III interferons exacerbate lung immunopathology during Bordetella pertussis infection.
|12:30||Boehm Dylan – West Virginia University, USA|
Intranasal pertussis vaccine inhibits pathogenesis of Bordetella pertussis at the site of infection.
|12:50||Walking Lunch & poster viewing|
|14:30||Session 3: Immunity and Vaccination – cont.|
Chair: N. Carbonetti & F. Mascart
|14:30||Locht Camille – Institut Pasteur de Lille, France|
Development of the live attenuated BPZE1 pertussis vaccine.
|15:00||Lin Ang – Karolinska Institutet, Sweden|
Characterization of the immune responses in humans generated to the live Bordetella pertussis vaccine BPZE1.
|15:20||Abu-Raya Bahaa – BC Children’s Hospital Research Inst., Canada|
Immunizations in infants born to women immunized with pertussis-containing vaccines in pregnancy versus unimmunized women: systematic review and meta-analysis.
|15:40||Maynard Jennifer – The University of Texas at Austin, USA|
Anti-pertussis toxin humanized monoclonal antibodies provide pertussis prophylaxis in newborn baboons.
|16:00||Poster viewing & fresh drinks|
|17:30||Discussion about the Bordetella Society|
|19:30||Banquet at The Belgian Comic Strip Center|
Friday, April 12th 2019
|9:00||Session 4: Evolutionary and Genomic aspects of Bordetella|
Chair: E.T. Harvill & F.H. Damron
|9:00||Preston Andrew – University of Bath, UK|
The hidden genome of Bordetella pertussis.
|9:30||He Qiushui – University of Turku, Finland|
Surveillance of circulating Bordetella pertussis strains in Europe.
|10:00||Rohani Pejman – University of Georgia, USA|
Epidemiology and evolution of pertussis in the Netherlands.
|10:20||Weigand Michael – CDC, USA|
wgMLST scheme development and validation for improved molecular typing of Bordetella pertussis.
|11:00||Session 5: Bordetellae other than Bordetella pertussis in human and veterinary medicine|
Chair: D. Hozbor & C. Locht
|11:00||Harvill Eric – University of Georgia, USA|
Emergence of Bordetella species as pathogens.
|11:30||Nicholson Tracy – USDA, USA|
Contribution of the BvgR and RisAS regulons in Bordetella bronchiseptica biology.
|12:00||Yount Kacy – The Ohio State University College of Medicine, USA|
An acellular vaccine containing BcfA a an antigen and the sole adjuvant protects mice against laboratory and clinical isolates of Bordetella bronchiseptica.
|12:20||Gu Xin-Xing – NIH, USA|
NIAID/NIH funding resources for Bordetella research & product development.
|12:30||Round-table discussion: G. Renauld-Mongénie – F.H. Damron|
Short- and long-term solutions for the control of pertussis and other Bordetella diseases.